8 December 2017
ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron opens US office
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has established an office in Boston, MA, USA. This office will initially house the Company's US-based clinical, medical and scientific communications staff and reflects the Company's focus on clinical development activities in the US across its therapeutic programmes.
During 2018, the Company plans to have three placebo-controlled Phase IIb clinical trials running with its CTX and hRPC cell therapy candidates, in stroke disability and retinal diseases. All of these studies will be conducted in clinical trial centres across the US.
The establishment of a US office will enable the Company to more closely manage its relationships with the clinical research organisations and others involved in the conduct of these clinical trials as well as facilitating stronger ties with US-based key opinion leaders in the Company's areas of therapeutic focus.
Olav Hellebø, Chief Executive Officer of ReNeuron, said:
"We are delighted to have established operations in Boston, one of the US's most vibrant academic and commercial biotechnology hubs. The US is a major future market for our cell-based therapies and a presence on the ground represents a key element of ReNeuron's clinical and commercial development strategy as our therapeutic candidates move closer to market."
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com .
This information is provided by RNS